



ITW  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99-383-B1)

In re Application of:

John W. Belmont et al.

Serial No.: 10/803,738

Filing Date: March 18, 2004

For: Phosphatases Which Activate Map  
Kinase Pathways

Examiner: Unassigned

Group Art Unit: 1651

Confirmation No.: 8046

TRANSMITTAL LETTER

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
  - a) Seventh Supplemental Information Disclosure Statement;
  - b) U.S. PTO 1449 Form with copy of 7 references; and
  - c) Postcard.
2. With respect to fees:
  - a) No fee is required.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 13 day of October, 2005.

Respectfully submitted,

Date: Oct. 13, 2005

  
Emily Miao  
Registration No. 35,285



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99-383-B1)

In re Application of:	)	
	)	
John W. Belmont et al.	)	Examiner: Unassigned
	)	
Serial No.: 10/803,738	)	
	)	Group Art Unit: 1651
Filing Date: March 18, 2004	)	
	)	
For: Phosphatases Which Activate Map	)	Confirmation No.: 8046
Kinase Pathways	)	

**SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies<sup>1</sup> of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

1. Luche et al., Canadian Patent No. 2 337 670 published January 11, 2001
2. PCT Application No. WO 00/06728 published February 10, 2000
3. PCT Application No. WO 01/02581 published January 11, 2001

---

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to undersigned.

4. Henikoff et al., *Proc. Natl. Acad. Sci. USA*, Vol. 89, pp. 10915-10919 (November 1992)
5. Keyse, S.M., *Biochimica et Biophysica Acta*, Vol. 1265, pp. 152-160 (1995)
6. Marra et al., "The WashU-HHMI Mouse EST Project," unpublished (1996), [www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=1684006](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=1684006)
7. Xia et al., *Science*, Vol. 270, pp. 1326-1331 (November 1995)

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: Oct. 13, 2005

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive  
Chicago, Illinois 60606  
Telephone : (312) 913-0001  
Facsimile: (312) 913-0002

Respectfully submitted,



---

Emily Miao  
Registration No. 35,285

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 99,383-B1	<b>Serial No.</b> 10/803,738
<b>SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> John W. Belmont et al.	
		<b>Filing Date:</b> March 18, 2004	<b>Group:</b> 1651



### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes      No
	1	2 337 670	1/11/01	Canada	C12N	15/52	
	2	WO 00/06728	2/10/00	PCT			
	3	WO 01/02581	1/11/01	PCT			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	4	Henikoff et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 10915-10919 (November 1992)
	5	Keyse, S.M., <i>Biochimica et Biophysica Acta</i> , Vol. 1265, pp. 152-160 (1995)
	6	Marra et al., "The WashU-HHMI Mouse EST Project," unpublished (1996), <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1684006">www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1684006</a>
	7	Xia et al., <i>Science</i> , Vol. 270, pp. 1326-1331 (November 1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.